Evidence map›Paper›PMID 26094732›Full record

Trial reportAmerican journal of reproductive immunology (New York, N.Y. : 1989)2015

Levels of Genital Tract Defensins and Cytokines Differ between HIV-Uninfected US and African Women.

Kerry Murphy, Barbra A Richardson, Charlene S Dezzutti, Jeanne Marrazzo, Sharon L Hillier, Craig W Hendrix, Betsy C Herold

Abstract readClinical Trial, Phase IIComparative Study
In one paragraph

Trial report in American journal of reproductive immunology (New York, N.Y. : 1989), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Genetic predictors for bacterial vaginosis in women living with and at risk for HIV infection.American journal of reproductive immunology (New York, N.Y. : 1989) · 2024
    Article
  2. Review
  3. Antiviral Activities of Human Host Defense Peptides.Current medicinal chemistry · 2020
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kerry MurphyDepartment of Medicine, Division of Infectious Diseases, Albert Einstein College of Medicine, Bronx, NY, USA.
Barbra A RichardsonDepartment of Biostatistics, University of Washington, Seattle, WA, USA.
Charlene S DezzuttiDepartment of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Jeanne MarrazzoDepartment of Medicine, University of Washington, Seattle, WA, USA.
Sharon L HillierDepartment of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Craig W HendrixDepartment of Medicine (Clinical Pharmacology), Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Betsy C HeroldDepartment of Pediatrics, Division of Infectious Diseases, Albert Einstein College of Medicine, Bronx, NY, USA.

Funding

Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
Microbicide Trials NetworkU01AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2006 to 2010
$77.0M
Statistical and Data Management Center (SDMC): Microbicide Trials NetworkUM1AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BROWN, ELIZABETH RENATA · 2011 to 2021
$66.5M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
Laboratory Center (LC): Microbicide Trials NetworkUM1AI106707 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MELLORS, JOHN W, ROHAN, LISA CENCIA · 2014 to 2021
$27.1M
Core-010UL1TR001073 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI KELLER, MARLA J, SHAMOON, HARRY · 2013 to 2017
$21.3M
Leadership for HIV/AIDS Clinical Trials Networks; Microbicide Trials NetworkU01AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI RICHARDSON, BARBRA A · 2006 to 2010
$20.4M
Pharmacokinetics and Biodistribution of Antiretrovirals and HIV-1 in MacaquesU19AI103461 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI HEROLD, BETSY C. · 2013 to 2017
$13.2M
Training in HIV/AIDS Pathogenesis; Basic and Translational ResearchT32AI007501 · NIAID · YESHIVA UNIVERSITY · PI PRASAD, VINAYAKA R. · 1995 to 2024
$6.6M
Impact of HSV-2 on Female Genital Tract Mucosal Immunity & HIV InfectionR01AI065309 · NIAID · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI HEROLD, BETSY C. · 2005 to 2014
$5.1M
NCATS NIH HHS UL1 TR000005NCATS NIH HHS UL1 TR001073NIAID NIH HHS R01 AI065309NIAID NIH HHS T32 AI007501NIAID NIH HHS U19 AI103461NIAID NIH HHS UM1 AI068615NIAID NIH HHS UM1 AI068633NIAID NIH HHS UM1 AI106707
6 · The paper itself

Abstract

problemTo explore the impact of race and geographic region on biomarkers of HIV risk and vaginal health, differences in soluble immune mediators were measured in US versus African and US white versus US black women at enrollment into a phase 2 microbicide trial.

methodsLevels of soluble mucosal immune mediators and inhibitory activity against E. coli, which may serve as biomarkers of risk for HIV and other genital tract infections, were quantified in cervicovaginal lavage (CVL) collected from HIV-uninfected women in the United States (n = 73) and Africa (n = 73). Differences between groups were analyzed with multivariable logistic regression models for dichotomous variables and linear regression models for continuous variables.

resultsSecretory leukocyte protease inhibitor, lactoferrin, human beta defensins, interleukin (IL)-8, and interferon-gamma-induced protein-10 were significantly higher in US compared to African women in multivariable analysis, but only IL-1β was significantly different between US white and black women. E. coli inhibitory activity did not differ among groups in adjusted analyses.

conclusionDifferences in soluble mucosal immunity between US and African women may play an important role in women's risk for HIV and other genital tract infections and response to prevention strategies including vaginal microbicides and should be considered in future studies.

Indexed as

Black or African AmericanWhite PeopleAdolescentAdultAfricabeta-DefensinsBiomarkersChemokine CXCL10Cross-Over StudiesCytokinesEscherichia coliFemaleGeographyHIV-1HIV InfectionsHumansbeta-DefensinsBiomarkersChemokine CXCL10CXCL10 protein, humanCXCL8 protein, humanCytokinesIL1B protein, humanInterleukin-1betaInterleukin-8LactoferrinSecretory Leukocyte Peptidase InhibitorFemale genital tractHIVmucosal immunityracial disparitiessexually transmitted infections

Identifiers

PMID26094732
PMCPMC4573314

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.